Factors Associated with Gabapentin Misuse among People Who Inject Drugs in Appalachian Kentucky

References

• Alabama State Board of Health. (2019). Controlled substances list. Retrieved February 7, 2020, from https://www.alabamapublichealth.gov/publications/assets/controlledsubstanceslist.pdf
   Google Scholar
• Al-Tayyib, A., Thiede, H., Burt, R. D., & Koester, S. (2015). Unmet health care needs and hepatitis C infection among persons who inject drugs in Denver and Seattle, 2009. Prevention Science, 16(2), 330–340. https://doi.org/10.1007/s11121-014-0500-4
   PubMed Web of Science ®Google Scholar
• Anagnostopoulos, A., Abraham, A. G., Genberg, B. L., Kirk, G. D., & Mehta, S. H. (2018). Prescription drug use and misuse in a cohort of people who inject drugs (PWID) in Baltimore. Addictive Behaviors, 81, 39–45. https://doi.org/10.1016/j.addbeh.2018.01.024
   PubMed Web of Science ®Google Scholar
• Baird, C. R. W., Fox, P., & Colvin, L. A. (2014). Gabapentinoid abuse in order to potentiate the effect of methadone: A survey among substance misusers. European Addiction Research, 20(3), 115–118. https://doi.org/10.1159/000355268
   PubMed Web of Science ®Google Scholar
• Bastiaens, L., Galus, J., & Mazur, C. (2016). Abuse of gabapentin is associated with opioid addiction. Psychiatric Quarterly, 87(4), 763–767. https://doi.org/10.1007/s11126-016-9421-7
   PubMed Web of Science ®Google Scholar
• Berlin, R. K., Butler, P. M., & Perloff, M. D. (2015). Gabapentin therapy in psychotic disorders: A systematic review. The Primary Care Companion for CNS Disorders, 17(5). https://doi.org/10.4088/PCC.15r01821
   Google Scholar
• Bicket, M. C., Park, J. N., Torrie, A., Allen, S. T., Weir, B. W., & Sherman, S. G. (2020). Factors associated with chronic pain and non-medical opioid use among people who inject drugs. Addictive Behaviors, 102, 106172. https://doi.org/10.1016/j.addbeh.2019.106172
   PubMed Web of Science ®Google Scholar
• Brockbrader, H. N., Wesche, D., Miller, R., Chapel, S., Janiczek, N., & Burger, P. (2010). A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clinical Pharmacokinetics, 49(10), 661–669.
   PubMed Web of Science ®Google Scholar
• Bryant, J. (2014). Using respondent-driven sampling with ‘hard to reach’ marginalised young people: Problems with slow recruitment and small network size. International Journal of Social Research Methodology, 17(6), 599–611. https://doi.org/10.1080/13645579.2013.811921
   Web of Science ®Google Scholar
• Buttram, M. E., Kurtz, S. P., Cicero, T. J., & Havens, J. R. (2019). An ethnographic decision model of the initiation of gabapentin misuse among prescription and/or illicit opioid (mis)user. Drug and Alcohol Dependence, 204, 107554. https://doi.org/10.1016/j.drugalcdep.2019.107554
   PubMed Web of Science ®Google Scholar
• Buttram, M. E., Kurtz, S. P., Dart, R. C., & Margolin, Z. R. (2017). Law enforcement-derived data on gabapentin diversion and misuse, 2002-2015: Diversion rates and qualitative research findings. Pharmacoepidemiology and Drug Safety, 26(9), 1083–1086. https://doi.org/10.1002/pds.4230
   PubMed Web of Science ®Google Scholar
• Buttram, M. E., Kurtz, S. P., Ellis, M. S., & Cicero, T. J. (2019). Gabapentin prescribed during substance abuse treatment: The perspective of treatment providers. Journal of Substance Abuse Treatment, 105, 1–4. https://doi.org/10.1016/j.jsat.2019.07.011
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. (2020). U.S. opioid prescribing rate maps. Retrieved May 2, 2020, from https://.cdc.gov/drugoverdose/maps/rxrate-maps.html
   Google Scholar
• Cicero, T. J., Ellis, M. S., Surratt, H. L., & Kurtz, S. P. (2014). Factors contributing to the rise of buprenorphine misuse: 2008-2013. Drug and Alcohol Dependence, 142, 98–104. https://doi.org/10.1016/j.drugalcdep.2014.06.005
   PubMed Web of Science ®Google Scholar
• Dahlman, D., Kral, A. H., Wenger, L. D., Hakansson, A., & Novak, S. P. (2017). Physical pain is common and associated with nonmedical prescription opioid use among people who inject drugs. Substance Abuse Treatment, Prevention, and Policy, 12(1), 29. https://doi.org/10.1186/s13011-017-0112-7
   PubMedGoogle Scholar
• Dennis, M. L., Feeney, T., & Titus, J. C. (2013). Global appraisal of individual needs– short screener (GAIN-SS): Administration and Scoring Manual, Version 3. Chestnut Health Systems.
   Google Scholar
• Evoy, K. E., Covvey, J. R., Peckham, A. M., Ochs, L., & Hultgren, K. E. (2019). Reports of gabapentin and pregabalin abuse, misuse, dependence, or overdose: An analysis of the Food and Drug Administration Adverse Events Reporting System (FAERS). Research in Social & Administrative Pharmacy, 15(8), 953–958. https://doi.org/10.1016/j.sapharm.2018.06.018
   PubMed Web of Science ®Google Scholar
• Evoy, K. E., Morrison, M. D., & Saklad, S. R. (2017). Abuse and misuse of pregabalin and gabapentin. Drugs, 77(4), 403–426. https://doi.org/10.1007/s40265-017-0700-x
   PubMed Web of Science ®Google Scholar
• Global Appraisal of Individual Needs. (2016). Global appraisal of individual needs – Indivdiual (GAIN-I), version [GVER]: 5.7.6. Chestnut Health Systems.
   Google Scholar
• Goodman, C. W., & Brett, A. S. (2017). Gabapentin and pregabalin for pain - Is increased prescribing a cause for concern? The New England Journal of Medicine, 377(5), 411–414. https://doi.org/10.1056/NEJMp1704633
   PubMed Web of Science ®Google Scholar
• Heckathorn, D. D. (1997). Respondent-driven sampling: A new approach to the study of hidden populations. Social Problems, 44(2), 174–199. https://doi.org/10.2307/3096941
   Web of Science ®Google Scholar
• Khosla, N., Juon, H. S., Kirk, G. D., Astemborski, J., & Mehta, S. H. (2011). Correlates of non-medical prescription drug use among a cohort of injection drug users in Baltimore City. Addictive Behaviors, 36(12), 1282–1287. https://doi.org/10.1016/j.addbeh.2011.07.046
   PubMed Web of Science ®Google Scholar
• King, L. (2020). State-imposed restrictions on gabapentin. Retrieved February 7, 2020, from, https://www.medval.com/2020/01/08/state-imposed-restrictions-on-gabapentin/
   Google Scholar
• Michigan Department of Licensing and Regulatory Affairs. (2019). Gabapentin scheduled as controlled substance to help with state's opioid epidemic. Retrieved February 28, 2019, from https://www.michigan.gov/lara/0,4601,7-154-11472-487050–,00.html
   Google Scholar
• Mincher, T. (2018). Gabapentin is a Schedule V controlled substance as of July 1, 2018. Tennessee Veterinary Medical Association. Retrieved January 29, 2020, from http://tvmanet.com/2018/06/29/gabapentin-is-a-schedule-v-controlled-substance-as-of-july-1-2018/
   Google Scholar
• North Dakota State Board of Pharmacy. (2019). Gabapentin added as a Schedule V substance in the North Dakota Controlled Substanced Act. Retrieved February 7, 2020, from https://nabp.pharmacy/wp-content/uploads/2016/06/North-Dakota-Newsletter-June-2019.pdf
   Google Scholar
• Paquette, C. E., Syvertsen, J. L., & Pollini, R. A. (2018). Stigma at every turn: Health services experiences among people who inject drugs. The International Journal on Drug Policy, 57, 104–110. https://doi.org/10.1016/j.drugpo.2018.04.004
   PubMed Web of Science ®Google Scholar
• Paquette, D., Bryant, J., & de Wit, J. (2012). Respondent-driven sampling and the recruitment of people with small injecting networks. AIDS and Behavior, 16(4), 890–899. https://doi.org/10.1007/s10461-011-0032-x
   PubMed Web of Science ®Google Scholar
• Pauly, N. J., Delcher, C., Slavova, S., Lindahl, E., Talbert, J., & Freeman, P. R. (2020). Trends in gabapentin prescribing in a comercially insured US adult population, 2009-2016. Journal of Managed Care & Specialty Pharmacy, 26 (3), 246–252. https://doi.org/10.18553/jmcp.2020.26.3.246
   PubMed Web of Science ®Google Scholar
• Peckham, A. M., Ananickal, M., & Sclar, D. (2018). Gabapentin use, abuse, and the US opioid epidemic: The case for reclassification as a controlled substance and the need for pharmacovigilance. Risk Management and Healthcare Policy, 11, 109–116. https://doi.org/10.2147/RMHP.S168504
   PubMed Web of Science ®Google Scholar
• Peckham, A. M., Evoy, K. E., Ochs, L., & Covvey, J. R. (2018). Gabapentin for off-label use: Evidence-based or cause for concern? Substance Abuse: Research and Treatment, 12, 117822181880131–117822181880138. https://doi.org/10.1177/1178221818801311
   Web of Science ®Google Scholar
• Peckham, A. M., & Sclar, D. A. (2019). Combined gabapentinoid and opioid use. Annals of Internal Medicine, 170(12), 908–909. https://doi.org/10.7326/L19-0155
   PubMed Web of Science ®Google Scholar
• Quintiles IMS Institute (2017). Medicines use and spending in the U.S.: A review of 2016 and outlook to 2021. Retrieved December 4, 2019, from https://structurecms-staging-psyclone.netdna-ssl.com/client_assets/dwonk/media/attachments/590c/6aa0/6970/2d2d/4182/0000/590c6aa069702d2d41820000.pdf?1493985952
   Google Scholar
• Reeves, R. R., & Ladner, M. E. (2014). Potentiation of the effect of buprenorphine/naloxone with gabapentin or quetiapine. The American Journal of Psychiatry, 171(6), 691. https://doi.org/10.1176/appi.ajp.2014.13111526
   PubMed Web of Science ®Google Scholar
• Smith, R. V., Lofwall, M. R., & Havens, J. R. (2015). Abuse and diversion of gabapentin among nonmedical prescription opioid users in Appalachian Kentucky. The American Journal of Psychiatry, 172(5), 487–488. https://doi.org/10.1176/appi.ajp.2014.14101272
   PubMed Web of Science ®Google Scholar
• Staton, M., Ciciurkaite, G., Havens, J., Tillson, M., Leukefeld, C., Webster, M., Oser, C., & Peteet, B. (2018). Correlates of injection drug use among rural Appalachian women. The Journal of Rural Health, 34(1), 31–41. https://doi.org/10.1111/jrh.12256
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. (2019). FDA in brief: FDA requires new warnings for gabapentinoids about risk of respiratory depression. Retrieved May 2, 2020, from https://www.fda.gov/news-events/fda-brief/fda-brief-fda-requires-new-warnings-gabapentinoids-about-risk-respiratory-depression
   Google Scholar
• Vickers Smith, R., Boland, E. M., Young, A. M., Lofwall, M. R., Quiroz, A., Staton, M., & Havens, J. R. (2018). A qualitative analysis of gabapentin misuse and diversion among people who use drugs in Appalachian Kentucky. Psychology of Addictive Behaviors, 32(1), 115–121. https://doi.org/10.1037/adb0000337
   PubMed Web of Science ®Google Scholar
• Vickers Smith, R., Sun, J., Charnigo, R. J., Lofwall, M. R., Walsh, S. L., & Havens, J. R. (2020). Gabapentin drug misuse signals: A pharmacovigilance assessment using the FDA adverse event reporting system. Drug and Alcohol Dependence, 206, 107709. https://doi.org/10.1016/j.drugalcdep.2019.107709
   PubMed Web of Science ®Google Scholar
• Voon, P., Callon, C., Nguyen, P., Dobrer, S., Montaner, J., Wood, E., & Kerr, T. (2014). Self-management of pain among people who inject drugs in Vancouver. Pain Management, 4(1), 27–35. https://doi.org/10.2217/pmt.13.62
   PubMedGoogle Scholar
• Wallach, J. D., & Ross, J. S. (2018). Gabapentin approvals, off-label use, and lessons for postmarketing evaluation efforts. JAMA, 319(8), 776–778. https://doi.org/10.1001/jama.2017.21897
   PubMed Web of Science ®Google Scholar
• Wilens, T., Zulauf, C., Ryland, D., Carrellas, N., & Catalina-Wellington, I. (2015). Prescription medication misuse among opioid dependent patients seeking inpatient detoxification. The American Journal on Addictions, 24(2), 173–177. https://doi.org/10.1111/ajad.12159
   PubMed Web of Science ®Google Scholar